The class of parvalbumin α inhibitors, despite its designation, does not consist of direct-acting small molecule inhibitors that bind to parvalbumin and inhibit its function. Instead, it encompasses a group of compounds that indirectly influence the activity of parvalbumin α by modulating intracellular calcium dynamics and signaling pathways that can alter the availability of calcium ions that parvalbumin is known to bind. These compounds function by affecting various calcium channels, receptors, and intracellular calcium stores to decrease the overall calcium concentration within the cell or specific subcellular compartments.
The indirect inhibitors include calcium channel blockers like nimodipine, which reduce calcium influx through L-type calcium channels, thereby limiting the calcium available for parvalbumin to bind and buffer. Ryanodine and dantrolene are agents that influence the ryanodine receptors involved in calcium release from the sarcoplasmic reticulum, whereas compounds like 2-APB and TMB-8 act on the inositol triphosphate (IP3) receptors to modulate calcium signaling. By altering the release of calcium from intracellular stores, these inhibitors could affect the buffering capacity of parvalbumin. Mibefradil and bepridil, by modulating T-type calcium channels and multi-channel activity, could impact the action potential firing patterns and the resultant intracellular calcium dynamics, which indirectly affects parvalbumin's role. Gabapentin, despite its primary use, can also affect neuronal excitability and, consequently, intracellular calcium levels, thereby having an indirect influence on parvalbumin α. Flunarizine, by decreasing intracellular calcium concentrations, can alter the environment in which parvalbumin operates, affecting its physiological role in neurons. Each compound in this class operates by influencing the calcium signaling pathways that govern parvalbumin's role in the cell, which includes its ability to bind calcium ions and its involvement in modulating the dynamics of calcium for proper cellular function.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Dantrolene | 7261-97-4 | sc-500165 | 25 mg | $350.00 | 7 | |
Dantrolene interferes with the release of calcium from the sarcoplasmic reticulum by binding to the ryanodine receptor. As parvalbumin is involved in calcium sequestration and release, dantrolene can indirectly influence its function by altering calcium homeostasis. | ||||||
2-APB | 524-95-8 | sc-201487 sc-201487A | 20 mg 100 mg | $27.00 $52.00 | 37 | |
2-APB is an inositol triphosphate (IP3) receptor antagonist that impedes calcium release from internal stores. By modulating IP3-mediated calcium signaling, it could indirectly affect parvalbumin's role in calcium buffering. | ||||||
Ryanodine | 15662-33-6 | sc-201523 sc-201523A | 1 mg 5 mg | $219.00 $765.00 | 19 | |
Ryanodine binds to and modulates ryanodine receptors, affecting calcium release from the sarcoplasmic reticulum. This modulation can indirectly influence the buffering action of parvalbumin. | ||||||
Nimodipine | 66085-59-4 | sc-201464 sc-201464A | 100 mg 1 g | $60.00 $301.00 | 2 | |
Nimodipine is a calcium channel blocker with specificity for L-type channels in the central nervous system. It could indirectly impact parvalbumin by reducing the intracellular calcium that parvalbumin modulates. | ||||||
SK&F 96365 | 130495-35-1 | sc-201475 sc-201475B sc-201475A sc-201475C | 5 mg 10 mg 25 mg 50 mg | $101.00 $155.00 $389.00 $643.00 | 2 | |
SKF-96365 inhibits receptor-mediated calcium entry and store-operated calcium entry. This inhibition could decrease the intracellular calcium levels, thus affecting parvalbumin's activity. | ||||||
Gabapentin | 60142-96-3 | sc-201481 sc-201481A sc-201481B | 20 mg 100 mg 1 g | $52.00 $92.00 $132.00 | 7 | |
Although not a direct inhibitor, gabapentin binds to the α2δ subunit of voltage-gated calcium channels, potentially modulating neuronal excitability and calcium signaling, indirectly influencing parvalbumin function. | ||||||
Bepridil | 64706-54-3 | sc-507400 | 100 mg | $1620.00 | ||
Bepridil is a multi-channel blocker affecting calcium, sodium, and potassium channels, potentially altering the electrochemical gradient and intracellular calcium levels, thereby indirectly affecting parvalbumin. | ||||||
Flunarizine | 52468-60-7 | sc-337841 | 5 g | $560.00 | ||
Flunarizine is a calcium channel blocker that can decrease intracellular calcium concentrations. Reduced calcium levels could theoretically modify parvalbumin activity by altering its calcium buffering capacity. | ||||||